4.0 Article

MR Imaging Biomarkers in Oncology Clinical Trials

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mric.2015.08.002

关键词

DCE-MR imaging; DSC-MR imaging; Diffusion; CEST; Elastography; Hyperpolarized; Multiparametric

资金

  1. National Institutes of Health [NCI U01CA142565, NCI R25CA092043, NCI U01CA174706, NCI R01CA158079, NCATS KL2 RR024977, NIBIB 1R21EB020323, NSF CHE-1416268, NIH 1R21EB018014]
  2. National Science Foundation [NCI U01CA142565, NCI R25CA092043, NCI U01CA174706, NCI R01CA158079, NCATS KL2 RR024977, NIBIB 1R21EB020323, NSF CHE-1416268, NIH 1R21EB018014]
  3. Department of Defense [NCI U01CA142565, NCI R25CA092043, NCI U01CA174706, NCI R01CA158079, NCATS KL2 RR024977, NIBIB 1R21EB020323, NSF CHE-1416268, NIH 1R21EB018014]
  4. DOD CDMRP breast cancer award [W81XWH-12-1-0159/BC112431]
  5. Association of University Radiologist's GE Radiology Research Academic Fellowship
  6. Division Of Chemistry
  7. Direct For Mathematical & Physical Scien [1416268] Funding Source: National Science Foundation

向作者/读者索取更多资源

The authors discuss eight areas of quantitative MR imaging that are currently used (RECIST, DCE-MR imaging, DSC-MR imaging, diffusion MR imaging) in clinical trials or emerging (CEST, elastography, hyperpolarized MR imaging, multiparameter MR imaging) as promising techniques in diagnosing cancer and assessing or predicting response of cancer to therapy. Illustrative applications of the techniques in the clinical setting are summarized before describing the current limitations of the methods.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据